Healthcare utilisation ‐ not measured · treatment for asthma in adults and children with asthma and GORD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Final visual acuity between 20/20 and 20/40 at end of treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in final visual acuity between 20/20 and 20/40 at end of treatment;… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after treatment; topical corticosteroids · people with traumatic hyphema
It is very uncertain whether systemic or topical corticosteroids changes short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after… compared with placebo or control treatment (very low certainty).
1 finding from 1 review
Final visual acuity between 20/20 and 20/25 at end of treatment; topical corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in final visual acuity between 20/20 and 20/25 at end of treatment;… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
1 finding from 1 review
RR 0.84 [0.4, 1.78]
Studies not reported
Low
Nausea severity · adults and children having any type of surgical procedure under general anaesthesia, regional anaesthesia or sedation, as hospital…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of somatic symptoms at end of treatment · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Treatment response at end of treatment · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Healthcare use · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with somatoform disorders and medically unexplained physical symptoms
Psychological therapy probably leads to lower acceptability 1 ‐ proportion of participants withdrawing during… compared with usual care or waiting list (moderate certainty).
1 finding from 1 review
Dysfunctional cognitions, emotions, or behaviours (participant rated) at end of treatment Whitely Index · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · people with somatoform disorders and medically unexplained physical symptoms
Psychological therapy may leads to higher treatment response at end of treatment CGI‐improvement/Global… compared with usual care or waiting list (low certainty).
1 finding from 1 review
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Healthcare use · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Severity of somatic symptoms at end of treatment · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with somatoform disorders and medically unexplained physical symptoms
Psychological therapy showed no clear difference in acceptability 1 ‐ proportion of participants withdrawing during… compared with enhanced or structured care (moderate certainty).
1 finding from 1 review
Dysfunctional cognitions, emotions, or behaviours at end of treatment Whitely Index (different forms) · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Adverse events ‐ Withdrawn for medical reasons · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo (moderate certainty).
1 finding from 1 review